Olodaterol (BI1744)

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

Pulmonary Disease, Chronic Obstructive

Phase 3

12 / 48 Week Pivotal PFT vs PBO in COPD I

CompletedNCT00782210

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2008-11-30Updated: 2014-06-09

Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II

CompletedNCT01040793

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2010-01-31Updated: 2014-07-08

Related Papers

Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials.

2020-09-1738 citations

<p>A Post Hoc Holter ECG Analysis of Olodaterol and Formoterol in Moderate-to-Very-Severe COPD</p>

International Journal of COPD2020-08-017 citations

Effect of olodaterol once-daily on heart rate in GOLD 2–4 COPD patients

2017-09-01

Evaluation of the effects of olodaterol on exercise endurance in patients with chronic obstructive pulmonary disease: results from two 6-week crossover studies.

2016-07-0614 citations

One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2–4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis

COPD Journal of Chronic Obstructive Pulmonary Disease2015-02-1835 citations

The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2-4 COPD: results from two 6-week crossover studies.

2014-08-0934 citations